Navigation Links
Novel Hepatitis C Drug Holds Promise: FDA
Date:4/27/2011

WEDNESDAY, April 27 (HealthDay News) -- An experimental new drug that may treat hepatitis C more effectively than earlier medications will be reviewed Thursday by a panel of experts for the U.S. Food and Drug Administration.

Telaprevir, made by Vertex Pharmaceuticals of Cambridge, Mass., would be prescribed in combination with two existing drugs to help reduce levels of the virus, which can cause severe liver damage, according to documents posted by the FDA on its website in advance of the meeting.

While the older drugs -- pegylated interferon-alfa and ribavirin -- are intended to bolster the immune system's response to hepatitis, the new drug works differently, blocking protease, an enzyme that enables the hepatitis C virus to reproduce. Together, the combined medications may offer new hope for the thousands of Americans with the contagious liver disease.

"A drug like telaprevir does an amazing job clearing the virus, but there's a small portion that is just intrinsically less responsive and it's the job of the older drugs to clear up that mess that's left behind," Dr. Camilla Graham, Vertex's vice president for global medical affairs, told the Associated Press.

According to one of the Vertex studies reviewed by the FDA, 79 percent of hepatitis C patients treated for the first time with the three-drug cocktail -- telaprevir and the two older drugs -- were cured, compared to 46 percent of patients given the earlier drugs alone, the AP reported.

The three-drug combo also worked better than the earlier drugs for patients previously treated for hepatitis C. Sixty-five percent of the telaprevir patients were cured, compared with 17 percent of those taking the older medications, the news service said.

By adding telaprevir to the medication regimen, most patients are cured in six months, instead of 12 months, which reduces their exposure to uncomfortable side effects, the AP reported.

The new drug was less effective for blacks than whites, the FDA said.

On Wednesday FDA reviewers were expected to study a similar drug, boceprevir, made by Merck & Co.

Telaprevir's cure rates appear to be better than boceprevir's, the AP reported.

On Thursday, the committee of outside experts will be asked for its comments and recommendations on telaprevir. The FDA is not required to follow the advice of its advisory panels, but it usually does so.

The U.S. Centers for Disease Control and Prevention estimated 17,000 new hepatitis C virus infections in the United States in 2007. Many people with the disease have no symptoms until it has caused liver damage, sometimes so severe that a liver transplant is needed.

Until the early 1990s, when testing of the nation's blood supply became routine, hepatitis C was often contracted from blood transfusions. Today it is most commonly associated with injection drug use. It is also transmitted through sexual contact with an infected person, the CDC said.

Earlier this year, a study from the Johns Hopkins School of Public Health called for greater efforts to reduce the population of hepatitis C-infected injection drug users. That study found that new cases of hepatitis C were decreasing only among younger injection drug users who had recently starting using the drugs.

More information

To learn more about hepatitis C, visit the U.S. National Library of Medicine.

-- HealthDay staff

SOURCES: U.S. Centers for Disease Control and Prevention; Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. A potential novel drug-target for colorectal cancer treatment comes from the brain
2. Researchers identify novel pathophysiologic mechanism responsible for autoimmunity
3. Novel association between Parkinsons disease and prostate cancer
4. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
5. Penn researchers uncover novel immune therapy for pancreatic cancer
6. Novel Treatment for Pancreatic Cancer Under Study
7. Novel approaches to bacterial caries management: An efficacious solution in view?
8. Novel strategies target health care-associated infections
9. Novel clinical trial aims to reduce recurrence of aggressive breast cancer
10. A novel prognostic marker for biliary atresia
11. Genome sequencing used to assess a novel form of Clostridium botulinum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
Breaking Medicine Technology: